Refining CMV Transmission Risks Using gB2 Antibodies

Refining CMV Transmission Risks Using gB2 Antibodies

Cytomegalovirus (CMV) causes significant morbidity in newborns worldwide. Therefore, enhancing CMV fetal risk prediction is crucial for clinicians who manage primary infections during the first trimester. While valacyclovir effectively reduces transmission rates, identifying individual risk remains a challenge. Notably, recent research highlights the predictive power of specific maternal antibodies.

A recent study from Germany investigated how glycoprotein B2 (gB2)-specific IgG antibodies influence transmission risks. Researchers analyzed pregnant women who received high-dose valacyclovir after a primary CMV infection. Specifically, they found that women with gB2-specific antibodies had a much lower residual risk of passing the virus to their fetuses.

Improving CMV fetal risk prediction with gB2 testing

The presence of these specific antibodies effectively identifies a subgroup with minimal transmission risk. For instance, in the study, all transmissions occurred in women who lacked these antibodies. Consequently, this finding suggests that immunoblot analysis can significantly refine prenatal counseling. Furthermore, clinicians can use this data to tailor monitoring and interventions more accurately.

Additionally, the study focused on infections acquired during the periconceptional period and the first trimester. During these stages, the potential for severe fetal injury is highest. Therefore, having a more precise predictive tool is vital for expectant mothers. Moreover, the integration of antibody profiling provides a clearer clinical picture than standard serology alone.

Frequently Asked Questions

Q1: How does valacyclovir affect CMV transmission?

High-dose valacyclovir reduces the rate of vertical transmission from mother to fetus during primary infection by inhibiting viral replication.

Q2: Why are gB2 antibodies significant for fetal risk?

The presence of gB2-specific antibodies indicates a specific immune response that correlates with a significantly lower risk of transmission to the fetus.

References

1. Kagan KO et al. Predictive value of gB2 antibodies for maternal-fetal transmission after primary cytomegalovirus infection treated with valacyclovir. Ultrasound Obstet Gynecol. 2026 Mar 30. doi: 10.1002/uog.70206. PMID: 41906968.
2. Shahar-Nissan K, Pardo J, Mazkereth R, et al. Valacyclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial. Lancet. 2020;396(10258):1171-1178.
3. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the newborn: consensus recommendations on prevention, diagnosis, and management. Lancet Infect Dis. 2017;17(6):e177-e188.